Plasma proteomic evidence for increased Alzheimer's disease-related brain pathology after SARS-CoV-2 infection

Eugene P Duff*[1,2], Henrik Zetterberg[3,4,5,6,7,8], Amanda Heslegrave[5], Abbas Dehghan[9,1,10], Paul Elliott[9,1,10,11,12,13], Naomi Allen[14,15], Heiko Runz[16], Rhiannon Laban[6], Elena Veleva[6], Christopher D Whelan[17], Benjamin B Sun[16], Paul M Matthews [§ 2,1]

[1]UK Dementia Research Institute Centre at Imperial College London, London, UK, [2]Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK, [3]Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden, [4]Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden, [5]Department of Neurodegenerative Disease, UCL Institute of Neurology, University College London, London, UK, [6]UK Dementia Research Institute Centre at UCL, London, UK, [7]Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China, [8]Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, [9]Department of Epidemiology and Biostatistics, Faculty of Medicine, Imperial College London, London, UK, [10]MRC Centre for Environment and Health, Imperial College London, London, UK, [11]British Heart Foundation Centre of Research Excellence, Imperial College London, London, [12]National Institute for Health Research Biomedical Research Centre, Imperial College London, London, [13]Health Data Research UK at Imperial College London, Imperial College London, London, [14]Nuffield Department of Population Health, University of Oxford, Oxford, UK, [15]UK Biobank, Stockport, UK, [16]Translational Sciences, Biogen, Cambridge, MA, USA, [17]Neuroscience Data Science, Janssen Research & Development, Cambridge, MA, USA

*Communicating author: Eugene Duff e.duff@imperial.ac.uk
[§] Senior author: Paul Matthews p.matthews@imperial.ac.uk

Key Words: COVID-19, plasma proteomics, biomarkers, beta-amyloid(1-42), Alzheimer's disease, dementia, disease risk

Abstract

Viral infections have been linked to an increased risk for dementia. We investigated whether SARS-CoV-2 infection increases preclinical brain pathology associated with Alzheimer's disease (AD) by comparing changes in plasma biomarkers in UK Biobank participants with and without prior SARS-CoV-2 infection. We discovered an association between SARS-CoV-2 infection and reduced plasma Aβ42:Aβ40 concentration ratio. In older participants, SARS-CoV-2 infection was associated with both lower plasma Aβ42 and higher plasma pTau-181. These biomarker changes, which have been associated with beta-amyloid accumulation and prodromal AD, were associated with increased brain imaging signatures of AD, poorer cognitive scores, and worse assessments of overall health and appeared to be greater in participants who had been hospitalised with COVID-19. Protein biomarker risk scores for other diseases were also raised among individuals who had past SARS-CoV-2 infections. Our data provide support for the hypothesis that viral infections can accelerate prodromal AD pathology and highlight biomarker profiles indicative of an increased risk of dementia and systemic diseases after SARS-CoV-2 infection, particularly in older people.

Introduction

Exposures to infectious diseases in early life and adulthood have been linked to increased risk for neurodegenerative and other systemic disease (1–4). Viral encephalitis or meningitis, influenza, pneumonia and viral intestinal infections may all increase risks of Alzheimer's disease (AD) (1). Vaccinations to prevent these diseases may also have protective effects (5). A variety of central and peripheral mechanisms may underly these effects, including both tissue injury during the acute phase of infections or secondary inflammatory processes and subsequent sustained low-grade systemic elevations of proinflammatory cytokines (6–8). Increased susceptibility to several diseases, impairment of cognition, and brain structural changes have been reported as sequelae of SARS-CoV-2 infections, even amongst people who did not require hospitalisation or experience long-COVID (9–11). The causes, prevalence and duration of these effects remain uncertain. However, the global scale of the pandemic makes better understanding of the potential impact of COVID-19 for future dementias and other disease a public health priority (10,12).

Recently developed high-throughput plasma proteomic biomarkers provide biologically-based markers of risk predictive of risk or the onset of disease years in advance of a clinical diagnosis or even major symptomology (13–19). Amongst the best characterised plasma proteomic markers that are more specific for dementias are a relatively low beta amyloid-(1-42) ($A\beta_{42}$) and its ratio with beta amyloid-1-40) ($A\beta_{42}$:$A\beta_{40}$), high phosphorylated tau (pTau) proteins, high neurofilament light (NFL) (a non-specific marker of neuronal injury) and glial fibrillary acidic protein (GFAP), which is associated with astrocyte activation. A growing number of studies have identified changes in these and other plasma proteins prior to dementia diagnoses and brain amyloid positivity by PET (13,19–21). Changes in these dementia-related proteins have also been identified in those with COVID-19 (15,22). However, to better assess future population disease risk, patients should be studied for changes persisting beyond the acute infection, ideally in a longitudinal study design. Furthermore, given the association of proteomic biomarkers with genetic background, aging, and health status, analyses where possible should take these factors into account when estimating disease risk.

Here, we studied over 1200 UK Biobank participants longitudinally to test for post-acute changes in plasma proteomic biomarkers associated with AD and other systemic disease. We compared a SARS CoV-2 antibody-positive group with largely mild symptoms to a demographically matched control group without evidence of prior SARS-CoV-2 infection. We used two independent panels of plasma biomarkers. We first used plasma protein levels obtained from a high-throughput Olink Explore platform including over 1400 proteins. Combinations of changes in these proteins (ProteinScores) have previously been associated with systemic disease risk, providing the opportunity to assess the impact of SARS-CoV-2 infection on risk scores for a variety of diseases (16,23,24). The second Quanterix panel specifically targeted validated dementia biomarkers, including Aβ42, Aβ40, pTau-181, which were not in the Olink panel. The UK Biobank dataset allowed relationships to be evaluated alongside the extensive genetic, imaging and health data available. We investigated individual and multivariate biomarkers for longitudinal changes among SARS-CoV-2

antibody-positive cases relative to matched controls and assessed vulnerable subpopulations including *APOE*-ε4 carriers and older participants.

Results

Study Population

We studied plasma proteomic biomarkers of AD or dementia risk and brain images that were made available from 1252 case-control matched UK Biobank participants who had been recruited for a COVID-19 re-imaging study (626 matched case-control pairs, 331 female) (Fig. 1a)(10). Participants were 46-80 years of age at the pre-pandemic imaging assessment (Fig. 1b). SARS-CoV-2 infection was determined by at least one of: home-based lateral flow SARS-CoV-2 antibody test, PCR antigen (swab) test, GP records or public health records (Fig. 1c, see Methods). Symptoms related to COVID-19 in participants with documented infections ranged from mild to severe (20 of the participants were hospitalised for COVID-19 or its complications). Less than 10% of the participants reported persistent symptoms related to COVID-19 after recovery from acute infections. The SARS-CoV-2 positive cases were matched (based on age (+/- 6 months), sex, ethnicity (white/non-white), and location and date of initial imaging assessment (+/- 6 months) with controls without evidence of SARS-CoV-2 infection between the baseline and follow-up imaging assessments. However, some characteristics differed between case and control groups: more cases (n=12) than controls (n=6) were identified as “key workers” during the pandemic (p=0.035); household sizes were larger on average (p=0.011) and cases were 1.4kg heavier on average than controls (p=0.024). Blood samples were obtained at imaging assessment sessions prior to (May 2014 - March 2020) and during (February 2021 - February 2022) the UK COVID-19 pandemic (Fig. 1d,e). Intervals between the two assessment sessions ranged from 12-82 months, but there was no difference in assessment intervals between cases and controls (p=0.585) (Fig. 1f).

Single molecule array (Simoa) ultrasensitive measures of plasma neurofilament light (NfL), glial fibrillary acidic protein (GFAP), amyloid-β_{42}, amyloid-β_{40}, and pTau-181 were available for the case-control pairs (see Methods). A complete set of these data was available for 600 participants, although some of the biomarker data were available for all. Olink platform proteomic measurements of concentrations of 1452 proteins (including additional assays for NFL and GFAP) in the same plasma samples were available for 436 of the case-control pairs (25).



Figure 1 a. Experimental design. Protein concentrations were assayed from plasma samples acquired from the UK Biobank imaging assessment visits, the second of which was specifically recruited for the study of COVID-19. b. Distribution of participant ages at the pandemic assessment. c. Sources of evidence for case selection. Antibody - home-based lateral flow SARS-CoV-2 antibody test; Antigen - PCR antigen (swab) test; Health records: GP and/or hospital records d. Distribution of pre-pandemic assessment visit dates : e. Distribution of pandemic assessment visit dates f. Distribution of intervals between assessments. g. Estimated dates of COVID symptoms (from participants with antigen test results).

	Cases	Matched controls	p-value
Female	331/626	331/626	1.000
Age	60.20 (7.41)	60.21 (7.40)	0.324
Assessment interval (months)	37.58 (17.86)	37.50 (17.82)	0.572
Ethnicity (non-white)	46	54	0.466
Weight (kg)	77.09 (15.01)	75.61 (14.53)	0.024
Hip/waist ratio	1.16 (0.12)	1.16 (0.12)	0.823
BMI	26.56 (4.20)	26.23 (4.17)	0.098
BP-systolic (mmHg)	137.20 (19.21)	137.22 (18.61)	0.984
BP-diastolic (mmHg)	79.26 (11.03)	79.33 (10.78)	0.636
BP medication	53	46	0.530
Diabetes diagnosis	38	31	0.457
Cholesterol-lowering medication	47	44	0.828
Alcohol intake freq. score	3.19 (1.34)	3.18 (1.32)	0.949
Smokers	26	18	0.283
Age completed education	16.89 (3.46)	16.71 (1.41)	0.769
Index of multiple deprivation	16.51 (11.80)	15.54 (12.13)	0.211
Household income (£1000s)	2.84 (1.70)	2.82 (1.75)	0.841
Number in household	2.46 (1.19)	2.30 (1.09)	0.007
Key worker	18	6	0.023
Working through COVID	16	6	0.053
General cognitive ability score	32.85 (7.26)	32.94 (7.59)	0.957
Prospective memory	0.87 (0.33)	0.87 (0.33)	1.000
Daily moderate activity (min)	65.14 (79.47)	54.78 (55.29)	0.003
General health (1-4)	3.02 (0.62)	3.09 (0.64)	0.069
Hand grip mean (kg)	32.05 (10.29)	31.73 (10.41)	0.590
Wheeze (chest)	526	525	0.838
APOE-ε4 count	0.28 (0.49)	0.26 (0.48)	0.666

Table 1. Comparisons of baseline characteristics of cases and controls. P-values reflect paired t-tests across matched case and control pairs (uncorrected). BMI: Body Mass Index, BP: blood pressure, BP medication: Prescribed anti-hypertensive medications.

SARS-CoV-2 infection associated with raised plasma proteomic disease risk scores

We first investigated whether recently defined multivariate plasma protein concentration changes associated with disease risk (ProteinScores) derived from Olink Explore plasma protein biomarkers in 47,600 UK biobank participants (16) provided evidence for increased

systemic disease risks following SARS-CoV-2 infection. As these risk scores were derived and validated on participants below the age of 73 years, we limited our analysis to this subset of our case-control cohort (n=353 pairs). Disease risks did not differ between cases and controls in the pre-pandemic assessment visit. We fit linear models describing each participant's pandemic-session plasma protein levels in terms of pre-pandemic proteomic levels, time interval between the two samples, age, sex, body mass index (BMI) and case-control status for each score (see Online Methods). Diseases where the contribution of the case-control status term in the model indicated significantly greater increases in proteomic risk scores in the SARS-CoV-2 infection group relative to controls, included type 2 diabetes (False Discovery Rate [FDR] significant* p-value, p=0.00072*), chronic obstructive pulmonary disease (COPD) (p=0.0055*), ischaemic stroke (p=0.0047*), heart disease (p=0.011*), and endometriosis (p=0.015*) (Figure 2). The magnitude of these changes is consistent with recent epidemiological reports of increased incidence of some of these diseases after the pandemic (26). SARS-CoV-2 infection did not appear to simply reflect a general acceleration of aging, as it did not affect all Olink ProteinScore disease risks (all disease risks but endometriosis show strong associations with age).

Notably, the Olink ProteinScores for AD and other dementias did not change significantly after SARS-CoV-2 infection. However, plasma biomarkers related specifically to AD-related amyloid or tau pathology were not assayed in the Olink panel (which included only the general brain pathology biomarkers NFL, GFAP, and Brevican core protein, an extracellular matrix protein enriched around synapses) (27).



Figure 2 SARS-CoV-2 related increases in Olink ProteinScore disease risk scores(16). Plots show SARS-CoV-2 effect weighting parameter in model of change of scores between assessment visits. Due to the ProteinScore disease risk training data, results are from participants <73 years. (*) reflects FDR corrected significance, alpha=0.05.

The plasma Aβ42:Aβ40 ratio reduced after SARS-CoV-2 infection

To explore potential effects of SARS-CoV-2 on preclinical AD brain pathology with greater sensitivity, we used ultrasensitive Simoa assays of plasma Aβ40, Aβ42, pTau-181, NFL and GFAP, measured at two time points to investigate longitudinal changes in these protein biomarkers between the periods before and after SARS-CoV-2 infection(13,28). Plasma beta-amyloid and pTau measures are sensitive and specific biomarkers of neurodegeneration; plasma Aβ42 concentration and the Aβ42:Aβ40 ratio decrease and plasma pTau-181 increases with brain amyloid accumulation and clinical progression of AD (13,21,29,30). While not specific for AD, concentrations of GFAP and NFL are also found to increase in plasma in early AD (20,31,32).

We first characterised concentrations of these biomarkers in plasma at the time of the first assessments across the study population (cases and controls) at baseline (before the

pandemic). We found that Aβ42 (p=0.035) and Aβ42:Aβ40 (p<0.001*) levels were lower and GFAP concentrations were higher (p=0.012*) in participants who were heterozygous for *APOE-ε4* (relative to *APOE-ε3* homozygotes) (Fig 3a-c). Plasma Aβ40, pTau-181, GFAP and NFL concentrations increased , while Aβ42:Aβ40 ratio decreased with age (linear associations with age, all p<0.001*). Aβ42:Aβ40 was slightly lower (-2.3%, p=0.01) at baseline in cases, but this difference was not significant (-1.4%, p=0.292) when an extended set of covariates were included in the model, including blood pressure, key worker status, and household size (supp table 8). Additional associations between protein markers, lifestyle and genetic variables are shown in Fig 3d and Supplementary Table 4.

We then applied the same linear modelling approach used for the ProteinScores analysis to assess changes in Simoa protein levels following SARS-CoV-2 infection relative to controls, taking advantage of longitudinal assessments, as well as the matched case-control design. The plasma Aβ42:Aβ40 ratio showed significantly greater reductions between pre-pandemic and pandemic assessment visit samples for cases (i.e. participants with SARS-CoV-2 infection in the time interval between the first and second blood sample) than for the matched control group (i.e. participants who were not infected over that period) (Table 3, p=0.001*). A similar difference was found when an extended model of covariates was used. These COVID-related differences in protein levels are comparable in magnitude to approximately 4 years of healthy aging (-0.5% per year, as estimated from the pre-pandemic cross-sectional data model) or the independent effect of *APOE-ε4* heterozygosity (Fig 3b-d).

Greater reductions in the Aβ42:Aβ40 ratio amongst cases were associated with greater reported severity of reported symptomatic infections: cases with COVID-19 who were hospitalised showed over twice the magnitude of reduction relative to non-hospitalised participants with COVID-19 (beta estimate: -0.0014 vs -0.0041). Hospitalised participants also showed increases in plasma IL6 with the Olink assay that were not found in cases who were not hospitalised (p=0.011*). While SARS-CoV-2 vaccination and *APOE* genotype both have been associated with COVID-19 severity previously (33,34) our analyses showed no detectable effects of these factors on plasma protein changes amongst the cases.



*Figure 3 Age and APOE variant effects on a. amyloid-beta-1-42 (Aβ42) b. Aβ42:Aβ40 ratio and. c. Glial fibrillary acidic protein (GFAP) in the total case and control population at pre-pandemic assessment visit (baseline). APOE variants correspond to combinations of the 3 major APOE alleles: ε2, ε3, and ε4 (risk variant). d. Associations between baseline plasma protein measures (abscissa) and demographic variables (ordinate) for the total population. Shading shows the magnitudes of correlations, where model parameter fits in models controlling for age and sex (p<0.05; * FDR significant). BMI: body mass index, BP: blood pressure, pTau-181: phosphorylated Tau 181, NfL, neurofilament light.*

Assay	Case/Control status	Age(y)	Genetic Sex	Assessment Interval (d)	BMI (pandemic)
Aβ40	0.7764 (p=0.170)	0.4178 (p=0.000**)	-1.2404 (p=0.133)	0.0015 (p=0.049*)	0.1381 (p=0.142)
Aβ42	-0.0948 (p=0.073)	0.0058 (p=0.226)	-0.0828 (p=0.212)	0.0001 (p=0.081)	0.0002 (p=0.974)
Aβ42:Aβ40	-0.0015 (p=0.001**)	-0.0001 (p=0.002**)	0.0000 (p=0.934)	-0.0000 (p=0.768)	-0.0001 (p=0.027**)
pTau-181	-0.0027 (p=0.558)	0.0078 (p=0.000**)	0.0900 (p=0.000**)	-0.0000 (p=0.838)	-0.0052 (p=0.016**)
NfL	-0.0040 (p=0.614)	0.0072 (p=0.000**)	-0.0115 (p=0.411)	0.0000 (p=0.001**)	-0.0065 (p=0.000**)
GFAP	-0.0024 (p=0.567)	0.0090 (p=0.000**)	-0.0441 (p=0.003**)	0.0000 (p=0.963)	-0.0067 (p=0.000**)

Table 2: Linear model estimates of proteomic levels in relation to case/control status and key covariates. Table shows model fits and p-values associated with case / control status (case=+1), age, sex (male=+1), the time interval between sessions (days), and BMI (body mass index). Aβ42:Aβ40 shows significant effect of case/control status, corresponding to lower values in case (SARS-CoV-2 infection) group. (**) indicates significant, FDR corrected by column, alpha=0.05.

Aβ42 decreases and pTau-181 increases after SARS-CoV-2 infection in older participants

Age is a risk factor both for AD and for the severity of COVID-19(35). We hypothesised that participants who were older or had other risk factors for neurodegenerative disease would be more likely to show changes in biomarkers reflecting neurodegenerative pathology. We applied a previously described age-weighting regressor from a model of increases of COVID-19 severity with age (10,35) to derive a SARS-CoV-2 infection regressor weighted for age (see Methods). When this interaction regressor was included in the model, it identified greater SARS-CoV-2-related increases relative to controls for pTau-181 ($p=0.018^*$) and relative decreases for Aβ42 ($p=0.022$) (Supplementary Table 5), with an apparent divergence in protein concentrations beginning around 70 years of age (Fig 4) (not seen for the plasma Aβ42:Aβ40 ratio).



Figure 4 Age and SARS-CoV-2 for plasma protein levels a. Aβ42 b. Aβ40 c. Aβ42:Aβ40 d. pTau-181 Plots show 7-year rolling mean with 90% CIs.

We then tested whether participants with higher values of an AD neuroimaging brain phenotype prior to the pandemic show greater plasma biomarker changes with SARS-CoV-2 infection. This brain imaging signature was previously developed from MRI volumetric and cortical thickness measures in the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (36), and was associated previously with higher rates of AD and lower memory and cognitive scores among UK Biobank participants (36). We found that higher values of this signature (after adjustment for age) were associated greater increases in pTau-181

(p=0.012*) and greater reductions in Aβ42 (p=0.0009*) after SARS-CoV-2 infection relative to the matched controls (Supplementary Table 6).

Associations between SARS-CoV-2 infection and changes in neuroimaging, cognitive performance, and general health measures

Finally, we assessed how plasma proteomic changes after SARS-CoV-2 infection relate to changes in brain imaging, cognitive performance, and health status. Previous work using the UK Biobank COVID-19 imaging data identified changes in brain structure after SARS-CoV-2 infection in an age-dependent manner (10). We found a corresponding trend for the Alzheimer's Disease Neuroimaging Initiative (ADNI)-derived AD structural brain phenotype: the signature tended to strengthen following SARS-CoV-2 infection in older participants, compared to their matched controls, based on an analysis with an age-weighted case/control regressor (p=0.053). This signature was not correlated with biomarker levels in the pre-pandemic visit, likely due to other sources of inter-subject variation in these measures. However, when protein levels were used as explanatory variables in models of change in the brain signature (both their pre-pandemic levels and change between the two assessment sessions; see Methods), lower pre-pandemic levels of Aβ42 (p=0.009*) and Aβ42:Aβ40 (p=0.040) were associated with greater increases in AD brain signature scores. Additionally, increases in pTau-181 (p=0.012*) and, to a lesser extent, NfL (p=0.030) between visits were associated with increased AD brain signature scores.

To measure cognitive performance, we evaluated a measure of general cognitive ability derived from UK Biobank cognitive tests (see Methods) (37). We found these scores were almost 2-fold lower after SARS-CoV-2 infection than could be accounted for by aging alone (2.2% relative to baseline age-related differences in cognitive ability of 1.16%/year (p=0.019*). There was a trend for an association between reductions in cognitive ability scores and increased plasma pTau-181 in older participants (p=0.024, not significant with FDR for the multiple tests across proteins).

Records of general health status relevant to known co-morbidities of COVID-19(38) were limited in the assessment visits. However, participants were asked to rate their overall health between poor and excellent. At the pre-pandemic assessment, these ratings showed a modest negative association with Aβ42 (p=0.001*) and Aβ40 (p=0.0024*) and a positive association with pTau-181 (p=0.009*). SARS-CoV-2-positive participants showed greater deterioration in their overall health ratings (3.4% p=0.011*), from a slightly lower baseline, across age groups. These changes also showed an association with changes in Aβ42 (p=0.026) and Aβ42:Aβ40 (p=0.039) levels (not significant FDR).

Discussion

SARS-CoV-2 infections can have profound, various and long-lasting effects on human health, producing persistent raised levels of illness and mortality since the pandemic, even in people who experienced only clinically mild cases of COVID-19(26,39). Here, using longitudinal ultrasensitive Simoa platform plasma Aβ and pTau measures that are relatively specific and sensitive for AD with a demographically-matched case-control design, we discovered plasma proteomic biomarker evidence for greater risks of AD after SARS-CoV-2 infection amongst UK Biobank participants who largely experienced mild to moderate symptoms. Our results suggest that SARS-CoV-2 accelerates preclinical progression of brain pathology associated with AD.

We found SARS-CoV-2 infection to be associated with greater reductions in Aβ42:Aβ40 between pre-pandemic and pandemic assessment visits. These directions of change, which are associated with increased AD risk, were reported previously for acute COVID-19 cases (15,40). Moreover, correlated decreases in plasma Aβ42 and increases in pTau-181 were seen in older participants and those with MRI brain signatures of AD, adding to evidence of greater AD-related pathology and risks of future AD (13,28,29,41). Reductions of plasma Aβ42:Aβ40 have been found to track brain amyloid accumulation in cognitively normal participants(30) and plasma pTau may increase with later stages of pathological brain amyloid accumulation (21). Their clinical significance was suggested in our study by the observed relationships with greater cognitive deficits and decrements in measures of general health quality.

The observed mean magnitude of the reduction in plasma Aβ42:Aβ40 after SARS-CoV-2 infection was equivalent to 4 years of aging (based on the baseline pre-pandemic data for this participant group) and was 60% of the effect size of inheriting a single *APOE-ε4* allele. These changes are commensurate with the effects of prior influenza and pneumonia on AD risk reported previously in a study of infection-related disease risks in FinnGenn and UK Biobank (1). Effect sizes were larger in the subgroup from our study who were hospitalised for COVID-19, suggesting that the impact on brain pathology is likely to increase with greater severity of symptomatic infection.

There are a variety of mechanisms by which mild to moderate SARS-CoV-2 infection may increase cerebral beta amyloidosis. Beta amyloid production and aggregation can be potentiated by stress, infection and pathological conditions including diabetes, stroke and vascular disease (42,43). Interferon-induced transmembrane protein (IFITM1-3) expression is triggered by viral infection. These are γ-secretase modulators and increased incorporation of IFITM3 into the γ-secretase complex potentiates its activity, increasing Aβ production (44,45). SARS-CoV-2 also has neuroinvasive potential and could be neurovirulent in some people (46–48).

.

In addition to highlighting increased biomarker indicators of risk of dementia with SARS-CoV-2 infection application of the more general Olink plasma protein-based risk scores developed in an earlier UK Biobank study also provide evidence for greater predicted risks for diabetes, ischaemic stroke and heart disease, COPD, lung cancer and endometriosis in the subset of participants under the age of 72(16). This is consistent with emerging post-COVID-19 epidemiology data (49–52) and proteomic studies of samples from COVID-19 patients hospitalised with acute symptoms(15). These fluid biomarkers have not been reported previously in a prospective SARS-CoV-2 infection or COVID-19 case-control setting. The raised risk of many - albeit not all – diseases with SARS-CoV-2 infection raises the possibility that SARS-CoV-2 (and other infections) may accelerate aging in a generalised sense(53). It is likely that infections can have both general and specific impacts on disease risks, and will impact individuals differently depending on the aging status different organ systems (1,19).

While our study was able to combine fluid biomarkers, imaging data, cognitive performance, and other covariates in a longitudinal case-control design, it has limitations. We relied on data linkage to hospital records and retrospective reports for information concerning symptoms associated with SARS-CoV-2 infections, limiting our ability to investigate relationships between the clinical severity of infections and biomarker changes; also, the observational nature of our analyses precludes making causal inferences. The retrospective case-control design was able to match participants for many, but not all major risk factors for COVID-19. While analyses controlled for other known risk factors, the small baseline differences in plasma biomarker concentrations between the case and control groups suggest there may be additional, uncontrolled susceptibility factors that distinguish between the SARS-CoV-2 infection and control groups. Plasma proteomics remain noisy, and the Aβ and pTau proteins studied here have yet to be tested at large scale, such that variations in their dynamics in the population are not well enough understood for clinically reliable risk scores to be developed. While Aβ and pTau are proteins strongly linked to AD and neurodegeneration, they also can vary with conditions other than AD. For example, concentrations of these proteins showed associations with a range of other traits in our dataset: Aβ40 and Aβ42, but not Aβ42:Aβ40, were correlated with blood pressure and its medications (54) and P-Tau was negatively correlated with BMI. However, the observed SARS-CoV-2 infection-related effects remained when these factors were included as potential confounders in the models. Finally, generalisation of our results to the wider population must be done with care: the UK Biobank sample population is not representative of the general population by many measures(55).

In conclusion, our study, along with earlier studies suggesting increased rates of dementia diagnosis following COVID-19(56), suggests that public health planning should take into account the possibility of increased rates of AD and systemic diseases in the coming years due to the COVID-19 pandemic. The relationships described here are unlikely to be specific for SARS-CoV-2 and may reflect more general effects of systemic viral or other infections on the aging brain. This highlights the need to prioritise pandemic preparedness as part of a strategy for reducing the future long-term burden of dementia and other chronic diseases, as well as for the impact of the acute infections.

Online Methods

Ethics

The UK Biobank is approved by the North West Multi-Centre Research Ethics Committee (MREC) to obtain and share data and samples from volunteer participants. Written informed consent was obtained from all participants (http://www.ukbiobank.ac.uk/ethics/).

Design

This study analyses Simoa ultra-sensitive assays of dementia-related proteins taken from blood-plasma obtained from participants in the UK Biobank COVID-19 repeat imaging study)(10). This study identified Case and Control participants from those who had taken part in the UK Biobank imaging enhancement(57), which comprises a comprehensive imaging assessment at one of four dedicated sites. Over 40,000 participants had been assessed prior to the COVID-19 pandemic. Inclusion criteria and other details are described in https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/casecontrol_covidimaging.pdf.

Participants were identified as being SARS-CoV-2-positive by the UK Biobank if (a) there were positive diagnostic antigen tests identified in the linkage to health-related records, (b) COVID-19 was reported in their primary care (GP) data or hospital records, or (c) two home-based lateral-flow antibody tests provided by the UK Biobank were positive (Fortress Fast COVID-19 Home test, Fortress Diagnostics and ABC-19TM Rapid Test, Abingdon Health). Both diagnostic antigen test and GP/hospital records were accompanied by data permitting estimation of date of COVID-19 infection.

For the 626 cases analysed here, SARS-CoV-2 infection was determined from mixed sources: 358 had a GP diagnosis of COVID-19 , 438 had record of a positive diagnostic antigen test prior to the assessment, and 467 returned positive on home-based antibody lateral flow test kits (Fig 1b). 24 participants had SARS-CoV-2 infection determined during a period of hospitalisation, for which 20 had COVID-19 listed as a primary cause. Two participants were excluded for having a prior dementia diagnosis (vascular dementia), identified from hospital inpatient records.

Control participants were selected as those who had negative antibody test results, and / or no other record of confirmed or suspected COVID-19 from available data. Control participants were matched to positive cases based on five characteristics: sex, ethnicity (non-white/white), date of birth (+/- 6 months), the location of first imaging assessment, and the date of this assessment (+/- 6 months). Further details of case and control identification are provided in the above link and (10).

Proteomic assay acquisition and pre-processing

Aβ40, Aβ42, NfL and GFAP concentrations were measured using the Simoa Human Neurology 4-Plex E assay (Quanterix). The Simoa P-tau181 Advantage Kit was used to measure P-tau181 concentration. All measurements were made on an HD-X instrument (Quanterix) with one round of experiments and a single batch of reagents. Technicians were blinded to participant case-control status and from which assessment visit a sample was taken from. Measurements were all above limit of detection and coefficients of variation within analytes were below 10%.

Anonymised data from 1256 participants were integrated with phenotype data via a UK Biobank key. Four participants were excluded for data being only available for one of the two imaging sessions. P-tau181, NfL, and GFAP markers showed positively skewed distributions and were log-normalised. For each biomarker, outliers were identified as measurements more than 8 times the Median Absolute Deviation (MAD) and excluded from the analysis. PCR plate IDs were also regressed out from the data. There was no significant imbalance of outliers or plate IDs across cases and controls. Cases and controls were matched according to UK Biobank field 4100 with 609 case-control pairs identified. 1220 participants and 583 matched case-control pairs had complete proteomic data. All analyses were performed on matched data, except (as noted) when key covariates of interest were missing from a set of participants. The Simoa Neurology assays showed patterns of covariance across participants closely matching previous reports (Fig 5) (58).



Figure 5 Correlations between Simoa Ultrasensitive neurology assays. Diagonal reflects correlations of protein levels between pre-pandemic and pandemic assessment visits.

Olink Proteomics

We used Olink Explore proteomic data from the Pharma Proteomics Project (PPP) which assayed samples from 54,219 UK Biobank participants across the different assessment sessions (25). Available data from the COVID-19 imaging assessment sessions for our case/control matched pairs comprised 436 matched participant pairs for which 1474 proteins from Cardiometabolic, Inflammation, Neurology and Oncology Olink panels were assayed. The Olink 3072 Explore platform extension data were not available for this COVID-19 case-control matched assessment visits. Available Olink proteins included NFL and GFAP which were also profiled in the Simoa assays. These markers were positively correlated to their Simoa counterparts (r=0.70 and 0.53 respectively).

We used these data to estimate and analyse the impact of SARS-CoV-2 on disease risk scores (ProteinScores) for 19 diseases and other outcomes (16). We assessed all diseases for which ProteinScores were available to provide the context of broader changes in disease risk for the AD-focused investigation. The ProteinScores risk scores have been developed from the UK Biobank Olink data using penalised Cox regression to estimate risk models linking the Olink data from the primary UK Biobank assessment sessions with health outcomes from linkage to over 16 years of electronic health data. We generated these risk scores for protein profile data from the COVID-19 imaging assessment sessions. The data were rank-base inverse normal transformed and rescaled to match the processing applied in the generation of the ProteinScores. Disease weight scores were downloaded from the publication website and applied to the data(16). These risk scores were analysed for change using the statistical models outlined below. As these associations are strongly age-dependent and were derived and validated on participants below the age of 72, we focused on this subset of our cohort.

Phenotypic data processing

Primary data for the study comes from the two imaging assessment sessions. Genetic and phenotypic data, including imaging and health records were available for all participants who took part in the COVID-19 reimaging project. Symptomology analyses used data from the UK Biobank COVID-19 Serology Study(59). Data were parsed and cleaned using the FMRIB UK BioBank Normalisation, Parsing and Cleaning Kit, and integrated with other data modalities into a combined Python pandas data frame.

Genetics

APOE variant status was extracted from UK Biobank subject genotyping using PLINK-2.0(60). We extracted variants at SNPs *rs429358* and *rs7412* to identify participants' *APOE* status. Data was available for 1027 participants, with five genotypes: ε3ε3 (n=630), ε3ε4 (235), ε2ε3 (135), ε4ε4 (20), and ε2ε2(7). We used ε3ε3 genotype as reference when one was required. Genotyping of further AD and COVID-19 genes was performed using available and imputed chromosome data.

Imaging Data and neuroimaging AD phenotype and score

We used brain imaging-derived phenotypes (IDPs) made available through the UK Biobank showcase(61,62). To avoid the multiple testing challenge of neuroimaging measures and

provide an interpretable neuromarker for this dementia-targeted study we used a structural brain data AD phenotype developed on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset to generate MRI-based AD scores for each participant(36). The phenotype reflects a Bayesian machine learning neural network trained to predict the probability that a participant has AD from 155 FreeSurfer cortical volume and thickness measures. Monte Carlo dropout was used to approximate Bayesian inference within a two-layer neural network. This phenotype model trained on 736 individuals (331 AD) from the ADNI database, and validated on 5209 participants from the National Alzheimer's Coordinating Centre and 37,104 participants in the UK Biobank (36), where predicted at-risk participants showed cognitive profiles representative of AD.

IDPs were cleaned by removing outliers more extreme than eight times the median absolute deviation from the median for a given IDP (across pre-pandemic and pandemic assessment visits). Matching the training data pre-processing for the structural AD phenotype, IDPs were de-confounded for age, estimated total intracranial volume, and sex, and rescaled using normalisation statistics from the ADNI training set. Software to generate these signatures was downloaded from https://github.com/tjiagoM/adni_phenotypes . PyTorch was used to apply the trained model (https://wandb.ai/tjiagom/adni_phenotypes/runs/2cxy59fk) to UK Biobank IDPs.

Cognitive Scores

The UK Biobank includes a series of standard cognitive tests, but they can be individually unreliable, and do not together correspond to established tests for general or dementia-related cognitive scoring. A procedure to estimate a measure of general cognitive ability from the UK Biobank data has previously been developed using an external validation dataset (37). We used the resulting score weights to calculate an overall score for cognitive ability for participants in each assessment visit.

Statistical modelling

We assessed SARS-CoV-2 induced longitudinal change in proteomic biomarkers using linear models of protein levels in the pandemic samples in terms of pre-pandemic protein levels, the time between assessment visits, and a binary case-control status variable (10). Disease risk scores were modelled in the same manner. We fit basic and extended change models which included additional potential confounder variables. While case and control matching would largely control for age and interval between two acquisition sessions, matching was not exact, so age and length of interval between sessions were included in both models. The basic model also included sex, BMI, blood pressure, key worker status and household size to control for SARS-CoV-2 confounders and reduce noise. To determine whether observed changes remained after modelling out co-factors such as key worker status, household size, and blood pressure, we also fit an extended model including these and other variables. The extended models included further variables known or expected to change over the assessment period and with COVID-19 (Table 4).

As the impact of SARS-CoV-2 infection is expected to vary according to certain characteristics and vulnerabilities, we fit further models with interaction terms for characteristics including *APOE* status, hospitalisation, and pre-pandemic neuroimaging AD score. Past modelling studies of neuroimaging correlations of COVID-19 have used an exponentially age-weighted case-control regressor to reflect the greater vulnerability of the brain with age (10). The weighting $10^{\text{Age-Pandemic} \times 0.0524 - 3.27}$ was derived directly from the modelling of the relationship between age and COVID-19 symptom severity(35). As each of the protein markers we assessed could be expected to have distinct patterns of expression and change with respect to normal aging, SARS-CoV-2 infection and COVID-19, and the course of dementia, we assessed models including both an unweighted Case-Control variable, and models including the additional weighted variable.

In addition to protein levels and disease risk scores, we modelled several additional outcome measures: general cognitive ability score, neuroimaging AD score, and reported level of general health. These outcomes were modelled in the same manner as the protein levels above. To assess whether changes in these outcomes were associated with changes in protein scores, additional models were assessed which included as predictors the pre-pandemic levels of proteins and their change across assessment visits.

Linear models were also used to assess relationships between protein levels and specific UK Biobank variables at baseline, including age and sex as covariates. Linear models were fit using Ordinary Least Squares and tested model parameters using t-tests. As we had strong hypotheses regarding direction of SARS-CoV-2-induced change in protein levels based on prior literature, we used one-sided tests. Benjamini/Hochberg False Discovery Rate with alpha=0.05 was used to control for statistical testing of multiple hypothesis across proteins and/or covariates.

Data and code availability

All data is available upon application from the UK Biobank.

Code for analyses and figures will be shared from the UKDRI GitHub page.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 76059. We are grateful to the participants, researchers, and all UK Biobank staff for their contributions to enabling this research. We particularly acknowledge the efforts of the staff and the commitment of UK Biobank participants to allowing the acquisition of these data during the COVID-19 pandemic. We also want to acknowledge support for the conception, development, funding and interpretation of results of the study from Dr. Sally Johns of Biogen.

EPD is supported jointly by funding to PMM from the UK Dementia Research Institute and from the NIHR Imperial Biomedical Research Centre, in which he is a member of the Multiple Long-Term Conditions theme. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, and #ADSF-21-831377-C), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). PMM acknowledges generous personal support from the Edmond J Safra Foundation and Lily Safra and an NIHR Senior Investigator Award. His work additionally is supported by the UK Dementia Research Institute, which receives its funding from UK DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK and, for this research specifically, Biogen.

Competing interests

HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). PMM is a consultant for Biogen, Sudo Therapeutics, Nimbus, Astex, GSK and Sangamo. He received research funding for aspects of this work from Biogen and the UK DRI. He has research funding unrelated to this work from Biogen and Bristol Meyers Squibb.

References

1. Levine KS, Leonard HL, Blauwendraat C, Iwaki H, Johnson N, Bandres-Ciga S, et al. Virus exposure and neurodegenerative disease risk across national biobanks. Neuron. 2023 Apr 5;111(7):1086-1093.e2.

2. Ou YN, Zhu JX, Hou XH, Shen XN, Xu W, Dong Q, et al. Associations of Infectious Agents with Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease. 2020 Jan 1;75(1):299–309.

3. Muzambi R, Bhaskaran K, Smeeth L, Brayne C, Chaturvedi N, Warren-Gash C. Assessment of common infections and incident dementia using UK primary and secondary care data: a historical cohort study. The Lancet Healthy Longevity. 2021 Jul 1;2(7):e426–35.

4. Muzambi R, Bhaskaran K, Rentsch CT, Smeeth L, Brayne C, Garfield V, et al. Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records. Transl Psychiatry. 2022 Sep 15;12(1):1–11.

5. Debisarun PA, Gössling KL, Bulut O, Kilic G, Zoodsma M, Liu Z, et al. Induction of trained immunity by influenza vaccination - impact on COVID-19. PLOS Pathogens. 2021 Oct 25;17(10):e1009928.

6. Franceschi C, Campisi J. Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. The Journals of Gerontology: Series A. 2014 Jun 1;69(Suppl_1):S4–9.

7. Tejera D, Mercan D, Sanchez-Caro JM, Hanan M, Greenberg D, Soreq H, et al. Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome. The EMBO Journal. 2019 Sep 2;38(17):e101064.

8. Hosseini S, Michaelsen-Preusse K, Schughart K, Korte M. Long-Term Consequence of Non-neurotropic H3N2 Influenza A Virus Infection for the Progression of Alzheimer's Disease Symptoms. Frontiers in Cellular Neuroscience [Internet]. 2021 [cited 2023 Jun 26];15. Available from: https://www.frontiersin.org/articles/10.3389/fncel.2021.643650

9. Xu E, Xie Y, Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022 Nov;28(11):2406–15.

10. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022 Apr;604(7907):697–707.

11. Hampshire A, Trender W, Chamberlain SR, Jolly AE, Grant JE, Patrick F, et al. Cognitive deficits in people who have recovered from COVID-19. eClinicalMedicine [Internet]. 2021 Sep 1 [cited 2023 Dec 27];39. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00324-2/fulltext

12. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry. 2021 May 1;8(5):416–27.

13. Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration. 2021 Feb 19;16(1):10.

14. Saunders TS, Pozzolo FE, Heslegrave A, King D, McGeachan RI, Spires-Jones MP, et al. Predictive blood biomarkers and brain changes associated with age-related cognitive decline. Brain Communications. 2023 Jun 1;5(3):fcad113.

15. Wang L, Western D, Timsina J, Repaci C, Song WM, Norton J, et al. Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer's and coronary disease pathways. iScience [Internet]. 2023 Apr 21 [cited 2023 Jun 24];26(4). Available from: https://www.cell.com/iscience/abstract/S2589-0042(23)00485-6

16. Gadd DA, Hillary RF, Kuncheva Z, Mangelis T, Admanit R, Gagnon J, et al. Blood protein levels predict leading incident diseases and mortality in UK Biobank [Internet]. medRxiv; 2023 [cited 2023 Sep 14]. p. 2023.05.01.23288879. Available from: https://www.medrxiv.org/content/10.1101/2023.05.01.23288879v1

17. Carrasco-Zanini J, Pietzner M, Davitte J, Surendran P, Croteau-Chonka DC, Robins C, et al. Proteomic prediction of common and rare diseases [Internet]. medRxiv; 2023 [cited 2023 Dec 22]. p. 2023.07.18.23292811. Available from: https://www.medrxiv.org/content/10.1101/2023.07.18.23292811v1

18. You J, Guo Y, Zhang Y, Kang JJ, Wang LB, Feng JF, et al. Plasma proteomic profiles predict individual future health risk. Nat Commun. 2023 Nov 28;14(1):7817.

19. Oh HSH, Rutledge J, Nachun D, Pálovics R, Abiose O, Moran-Losada P, et al. Organ aging signatures in the plasma proteome track health and disease. Nature. 2023 Dec;624(7990):164–72.

20. Kim KY, Shin KY, Chang KA. GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Cells. 2023 May 4;12(9):1309.

21. Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020 Mar;26(3):379–86.

22. Lai YJ, Liu SH, Manachevakul S, Lee TA, Kuo CT, Bello D. Biomarkers in long COVID-19: A systematic review. Frontiers in Medicine [Internet]. 2023 [cited 2023 Jun 24];10. Available from: https://www.frontiersin.org/articles/10.3389/fmed.2023.1085988

23. Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C, et al. Plasma protein patterns as comprehensive indicators of health. Nat Med. 2019 Dec;25(12):1851–7.

24. Lindbohm JV, Mars N, Walker KA, Singh-Manoux A, Livingston G, Brunner EJ, et al. Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. Alzheimer's & Dementia. 2022;18(4):612–24.

25. Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023 Oct;622(7982):329–38.

26. Gaudet LA, Pillay J, Saba S, Zakaria D, Cheta N, Gardiner H, et al. Associations between SARS-CoV-2 infection and incidence of new chronic condition diagnoses: a systematic review. Emerg Microbes Infect. 12(1):2204166.

27. Jonesco DS, Karsdal MA, Henriksen K. The CNS-specific proteoglycan, brevican, and its ADAMTS4-cleaved fragment show differential serological levels in Alzheimer's disease, other types of dementia and non-demented controls: A cross-sectional study. PLoS One. 2020 Jun 19;15(6):e0234632.

28. Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019 Oct 22;93(17):e1647–59.

29. Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M, et al. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Alzheimer's Research & Therapy. 2018 Mar 20;10(1):33.

30. Fandos N, Pérez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst). 2017 Aug 30;8:179–87.

31. Palmqvist S, Insel PS, Stomrud E, Janelidze S, Zetterberg H, Brix B, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine. 2019 Dec;11(12):e11170.

32. Mattsson N, Andreasson U, Zetterberg H, Blennow K, for the Alzheimer's Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology. 2017 May 1;74(5):557–66.

33. Camerlingo C. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis [Internet]. European Review. 2022 [cited 2023 Dec 5]. Available from: https://www.europeanreview.org/article/28248

34. Safdari Lord J, Soltani Rezaiezadeh J, Yekaninejad MS, Izadi P. The association of APOE genotype with COVID-19 disease severity. Sci Rep. 2022 Aug 5;12(1):13483.

35. Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. European Journal of Epidemiology. 2020;35(12):1123.

36. Azevedo T, Bethlehem RAI, Whiteside DJ, Swaddiwudhipong N, Rowe JB, Lió P, et al. Identifying healthy individuals with Alzheimer neuroimaging phenotypes in the UK Biobank [Internet]. medRxiv; 2022 [cited 2023 Jul 10]. p. 2022.01.05.22268795. Available from: https://www.medrxiv.org/content/10.1101/2022.01.05.22268795v1

37. Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. PLOS ONE. 2020 Apr 20;15(4):e0231627.

38. Mizrahi B, Sudry T, Flaks-Manov N, Yehezkelli Y, Kalkstein N, Akiva P, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023 Jan 11;380:e072529.

39. Atchison CJ, Davies B, Cooper E, Lound A, Whitaker M, Hampshire A, et al. Long-term health impacts of COVID-19 among 242,712 adults in England. Nat Commun. 2023 Oct 24;14(1):6588.

40. Virhammar J, Nääs A, Fällmar D, Cunningham JL, Klang A, Ashton NJ, et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. European Journal of Neurology. 2021;28(10):3324–31.

41. Boulo S, Kuhlmann J, Andreasson U, Brix B, Venkataraman I, Herbst V, et al. First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays. Alzheimer's & Dementia. 2020;16(11):1493–503.

42. Zhang X, Fu Z, Meng L, He M, Zhang Z. The Early Events That Initiate β-Amyloid Aggregation in Alzheimer's Disease. Front Aging Neurosci. 2018 Nov 13;10:359.

43. Abbott A. Are infections seeding some cases of Alzheimer's disease? Nature. 2020 Nov 4;587(7832):22–5.

44. Hur JY, Frost GR, Wu X, Crump C, Pan SJ, Wong E, et al. The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease. Nature. 2020 Oct;586(7831):735–40.

45. Gholami M, Sakhaee F, Mirzaei Gheinari F, Sotoodehnejadnematalahi F, Ghazanfari Jajin M, Zamani MS, et al. Interferon-Induced Transmembrane Protein 3 rs34481144 C/T Genotype and Clinical Parameters Related to Progression of COVID-19. J Immunol Res. 2023 Jun 7;2023:2345062.

46. Fernández-Castañeda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022 Jul 7;185(14):2452-2468.e16.

47. Wei ZYD, Liang K, Shetty AK. Role of Microglia, Decreased Neurogenesis and Oligodendrocyte Depletion in Long COVID-Mediated Brain Impairments. Aging and disease. 2023 Sep 24;0.

48. Bauer L, Laksono BM, Vrij FMS de, Kushner SA, Harschnitz O, Riel D van. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. Trends in Neurosciences. 2022 May 1;45(5):358–68.

49. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Mar;28(3):583–90.

50. Wan EYF, Mathur S, Zhang R, Yan VKC, Lai FTT, Chui CSL, et al. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality: a prospective cohort in UK Biobank. Cardiovascular Research. 2023 Jun 15;119(8):1718–27.

51. Marín JS, Mazenett-Granados EA, Salazar-Uribe JC, Sarmiento M, Suárez JF, Rojas M, et al. Increased incidence of rheumatoid arthritis after COVID-19. Autoimmunity Reviews. 2023 Oct 1;22(10):103409.

52. Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022;65(6):949–54.

53. Argentieri MA, Xiao S, Bennett D, Winchester L, Nevado-Holgado AJ, Albukhari A, et al. Proteomic aging clock predicts mortality and risk of common age-related diseases in diverse populations [Internet]. medRxiv; 2023 [cited 2023 Dec 31]. p. 2023.09.13.23295486. Available from: https://www.medrxiv.org/content/10.1101/2023.09.13.23295486v1

54. Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma β-amyloid in Alzheimer's disease and vascular disease. Sci Rep. 2016 May 31;6(1):26801.

55. Schoeler T, Speed D, Porcu E, Pirastu N, Pingault JB, Kutalik Z. Participation bias in the UK Biobank distorts genetic associations and downstream analyses. Nat Hum Behav. 2023 Jul;7(7):1216–27.

56. Wang L, Davis PB, Volkow ND, Berger NA, Kaelber DC, Xu R. Association of COVID-19 with New-Onset Alzheimer's Disease. J Alzheimers Dis. 2022;89(2):411–4.

57. Littlejohns TJ, Holliday J, Gibson LM, Garratt S, Oesingmann N, Alfaro-Almagro F, et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nature Communications. 2020 May 26;11(1):2624.

58. Stevenson-Hoare J, Heslegrave A, Leonenko G, Fathalla D, Bellou E, Luckcuck L, et al. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Brain. 2023 Feb 1;146(2):690–9.

59. Bešević J, Lacey B, Callen H, Omiyale W, Conroy M, Feng Q, et al. Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study. J Epidemiol Community Health [Internet]. 2023 Nov 3 [cited 2023 Dec 10]; Available from: https://jech.bmj.com/content/early/2023/11/03/jech-2023-220569

60. Second-generation PLINK: rising to the challenge of larger and richer datasets | GigaScience | Oxford Academic [Internet]. [cited 2023 Dec 9]. Available from: https://academic.oup.com/gigascience/article/4/1/s13742-015-0047-8/2707533?login=false

61. Miller KL, Alfaro-Almagro F, Bangerter NK, Thomas DL, Yacoub E, Xu J, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nature Neuroscience. 2016 Nov;19(11):1523–36.

62. Alfaro-Almagro F, Jenkinson M, Bangerter NK, Andersson JLR, Griffanti L, Douaud G, et al. Image processing and Quality Control for the first 10,000 brain imaging datasets from UK Biobank. NeuroImage. 2018 Feb 1;166:400–24.

Extended Data

Covariate	Basic Model	Extended Model	Additional Models	UKB data-field ID(s)
Age	X	X		34,52,53
Genetic Sex	X	X		22001
Age(pandemic)-Age(pre)	X	X		34,52,53
BMI	X	X		21001
Age(pandemic)^2 – Age(pre)^2		X		34,52,53
Weight (kg)		X		21002
Hip/Waist Ratio		X		48,49
Blood Pressure (dia,sys)		X		4079,4080
Blood Pressure medications		X		6153
Cholesterol medications		X		6153
Ethnicity (White)		X		21000
Key Worker Status		X		28063
Household Size		X		709
Alcohol Intake Freq		X		1558
Smoking status		X		1239
Years of education		X		845
Deprivation		X		26410
APOE status		X	X	Genotyping
General Health			X	2178
AD PRS			X	26206
AD imaging phenotype			X	Freesurfer IDPs
General Cognitive Ability score			X	Cognitive test IDPs

Supplementary Table 3 UK Biobank Covariates used in analyses. BMI: Body Mass Index; AD PRS: Alzheimer's Disease polygenic risk score.

Assay	Ab40	Ab42	Ab42/Ab40	pTau-181	NfL	GFAP
Age	0.5078 (p=0.000**)	0.0024 (p=0.681)	-0.0004 (p=0.000**)	0.0105 (p=0.000**)	0.0260 (p=0.000**)	0.0250 (p=0.000**)
Genetic Sex	0.4157 (p=0.696)	0.0048 (p=0.956)	-0.0008 (p=0.281)	0.1056 (p=0.000**)	0.0050 (p=0.788)	-0.1020 (p=0.000**)
BMI	0.0865 (p=0.492)	-0.0103 (p=0.314)	-0.0002 (p=0.076)	-0.0066 (p=0.011**)	-0.0171 (p=0.000**)	-0.0143 (p=0.000**)
BP (sys)	-0.0687 (p=0.038**)	-0.0082 (p=0.002**)	-0.0000 (p=0.178)	-0.0018 (p=0.009**)	-0.0033 (p=0.000**)	-0.0020 (p=0.005**)
BP (dia)	0.0015 (p=0.978)	-0.0033 (p=0.442)	-0.0000 (p=0.259)	-0.0024 (p=0.029*)	-0.0043 (p=0.000**)	-0.0041 (p=0.000**)
Weight	0.0047 (p=0.909)	-0.0041 (p=0.216)	-0.0000 (p=0.115)	-0.0010 (p=0.219)	-0.0061 (p=0.000**)	-0.0053 (p=0.000**)
Hip/Waist Ratio	-6.2800 (p=0.309)	0.1243 (p=0.805)	0.0058 (p=0.192)	0.3009 (p=0.018**)	0.6117 (p=0.000**)	0.4033 (p=0.002**)
Alcohol Intake Freq	-0.4682 (p=0.233)	-0.0233 (p=0.469)	-0.0000 (p=0.994)	-0.0142 (p=0.079)	-0.0058 (p=0.413)	-0.0244 (p=0.003**)
Smoker	2.4211 (p=0.173)	-0.0283 (p=0.845)	-0.0021 (p=0.095)	-0.0110 (p=0.767)	-0.0017 (p=0.959)	-0.0246 (p=0.514)
Age Eduction Complete	0.4737 (p=0.454)	0.0598 (p=0.117)	0.0002 (p=0.426)	0.0025 (p=0.854)	0.0215 (p=0.026*)	0.0112 (p=0.337)
Deprivation	0.0417 (p=0.338)	0.0018 (p=0.605)	-0.0000 (p=0.859)	0.0001 (p=0.953)	-0.0005 (p=0.523)	-0.0005 (p=0.614)
Income	-0.0572 (p=0.852)	0.0154 (p=0.539)	0.0002 (p=0.390)	-0.0094 (p=0.133)	-0.0035 (p=0.525)	-0.0050 (p=0.444)
Number in Household	0.7023 (p=0.153)	0.0241 (p=0.549)	-0.0003 (p=0.358)	-0.0076 (p=0.454)	0.0004 (p=0.967)	0.0143 (p=0.171)
Ethnicity(White)	0.2279 (p=0.905)	-0.1195 (p=0.442)	-0.0012 (p=0.383)	-0.0376 (p=0.335)	-0.0223 (p=0.522)	-0.0625 (p=0.122)
Prospective Memory	1.4272 (p=0.339)	0.1104 (p=0.365)	0.0005 (p=0.639)	-0.0079 (p=0.796)	0.0184 (p=0.496)	0.0119 (p=0.704)
AD Neuroimaging Phenotype	0.6339 (p=0.421)	0.0378 (p=0.557)	-0.0004 (p=0.480)	0.0179 (p=0.269)	0.0044 (p=0.760)	0.0052 (p=0.756)
Cognitive Ability Score	0.1237 (p=0.156)	0.0118 (p=0.114)	0.0000 (p=0.734)	0.0003 (p=0.849)	0.0012 (p=0.452)	0.0030 (p=0.108)
General Health	-2.5983 (p=0.001**)	-0.1502 (p=0.024**)	0.0004 (p=0.515)	0.0438 (p=0.009**)	0.0288 (p=0.052)	0.0343 (p=0.047*)
APOE-e4 count	0.5725 (p=0.494)	-0.1606 (p=0.021**)	-0.0023 (p=0.000**)	0.0230 (p=0.187)	-0.0051 (p=0.736)	0.0451 (p=0.010**)
Case/Control status	0.1160 (p=0.910)	-0.1142 (p=0.174)	-0.0018 (p=0.016*)	-0.0121 (p=0.567)	-0.0311 (p=0.097)	-0.0197 (p=0.367)

Supp Table 4 Associations of protein biomarkers with UK Biobank variables at pre-pandemic assessment visit. Associations were determined from linear models including age and sex covariates. (*) p<0.05 uncorrected (**) p<0.05 FDR correction (alpha = 0.05).

Assay	Case/Control status	Case (age weighted)	Age	Sex	Assessment Gap	BMI (post)
Ab40	1.9382 (p=0.043*)	-1.2069 (p=0.932)	2.0305 (p=0.023*)	-1.3470 (p=0.104)	0.0009 (p=0.827)	0.1446 (p=0.124)
Ab42	0.0317 (p=0.637)	-0.1306 (p=0.022*)	0.0841 (p=0.849)	-0.0840 (p=0.207)	0.0001 (p=0.734)	0.0004 (p=0.955)
Ab42/Ab40	-0.0013 (p=0.026*)	-0.0002 (p=0.343)	-0.0003 (p=0.287)	0.0001 (p=0.895)	0.0000 (p=0.527)	-0.0001 (p=0.025*)
pTau-181	-0.0400 (p=0.942)	0.0383 (p=0.018**)	0.0289 (p=0.102)	0.0844 (p=0.000**)	0.0002 (p=0.037*)	-0.0051 (p=0.017**)
NfL	-0.0214 (p=0.868)	0.0180 (p=0.095)	0.0011 (p=0.475)	-0.0129 (p=0.360)	0.0001 (p=0.063)	-0.0065 (p=0.000**)
GFAP	-0.0024 (p=0.548)	-0.0000 (p=0.500)	-0.0075 (p=0.661)	-0.0441 (p=0.003**)	0.0001 (p=0.126)	-0.0067 (p=0.000**)

Supp Table 5 Parameter fits for linear model predicting proteomic levels in pandemic assessment session, including an interaction term with age-related COVID-19 symptom severity(10,35). The primary independent variable was protein level in pre-pandemic session. Table shows model fits and p-values associated with additional predictors: Case / Control status, severity weighted Case / Control status age, sex, the time interval between sessions, and BMI. NfL – neurofilament light; GFAP (**) indicates significant, FDR corrected by column, alpha=0.05.

Assay	Case/Control status	Case weighted NI sig	Neuroimaging sig	Age	Sex	Assessment Gap	BMI (post)
Ab40	-2.5235 (p=0.203)	-1.5966 (p=0.104)	0.5391 (p=0.273)	0.0161 (p=0.052)	-1.5670 (p=0.177)	0.0017 (p=0.702)	0.0188 (p=0.867)
Ab42	-0.5574 (p=0.012*)	-0.2064 (p=0.023*)	0.0697 (p=0.168)	0.0006 (p=0.342)	-0.1327 (p=0.159)	0.0003 (p=0.398)	-0.0040 (p=0.658)
Ab42/Ab40	-0.0026 (p=0.077)	-0.0004 (p=0.287)	0.0003 (p=0.287)	-0.0000 (p=0.599)	-0.0005 (p=0.439)	0.0000 (p=0.380)	-0.0001 (p=0.196)
pTau-181	0.1205 (p=0.042*)	0.0574 (p=0.024*)	-0.0249 (p=0.113)	0.0002 (p=0.217)	0.1196 (p=0.000**)	0.0002 (p=0.018*)	-0.0020 (p=0.438)
NfL	0.0529 (p=0.156)	0.0258 (p=0.119)	-0.0343 (p=0.013*)	0.0001 (p=0.582)	0.0013 (p=0.949)	0.0001 (p=0.088)	-0.0066 (p=0.001**)
GFAP	0.0346 (p=0.265)	0.0178 (p=0.219)	-0.0242 (p=0.068)	-0.0002 (p=0.261)	-0.0337 (p=0.110)	0.0002 (p=0.055)	-0.0062 (p=0.002**)

Supp Table 6 Parameter fits for linear model predicting proteomic levels in pandemic assessment session, including an interaction term with neuroimaging AD phenotype scores (36). The primary independent variable was protein level in pre-pandemic session. Table shows model fits and p-values associated with additional predictors: Case / Control status, phenotype weighted Case / Control status age, sex, the time interval between sessions, and BMI. NfL – neurofilament light; GFAP (**) indicates significant, FDR corrected by column, alpha=0.05.